Cytori, GE Healthcare Extend Distribution Pact

Cytori Therapeutics, Inc. has extended and modified its current distribution agreement with GE Healthcare. GE has rights to sell Cytori technology in the research markets in select European markets and in the U.S. In turn, Cytori has co-exclusive sales rights to the research markets and retains primary rights to sell in all clinical markets. The term of the agreement has been extended through 2011.

This agreement is specific to the Celution 800 and StemSource Systems and does not cover any other therapeutic applications or the PureGraft System. Select European countries covered by these terms include the U.K., France, Germany, Norway, Finland, Denmark, Sweden, Austria, Switzerland, Belgium, the Netherlands and Luxembourg for research and banking only.

“Cytori’s products are a valuable component to GE Healthcare’s regenerative medicine product portfolio,” said Konstantin Fielder, general manager of Cell Technologies at GE Healthcare Life Sciences. “Continuing our relationship with Cytori reflects our recognition of this emerging field and, in particular the importance of adipose-derived regenerative cells.”